Chao, Daniel

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 785

Artificial intelligence-based decision-making for age-related macular degeneration

Hwang, D.-K., Hsu, C.-C., Chang, K.-J., Chao, D., Sun, C.-H., Jheng, Y.-C., Yarmishyn, A. A., Wu, J.-C., Tsai, C.-Y., Wang, M.-L., et al. (2019) · Theranostics

Retinal Imaging and AnalysisRetinal Diseases and Treatments

Cited by 189

The lipid elongation enzyme ELOVL2 is a molecular regulator of aging in the retina

Chen, D., Chao, D. L., Rocha, L., Kolar, M., Nguyen Huu, V. A., Krawczyk, M., Dasyani, M., Wang, T., Jafari, M., Jabari, M., et al. (2020) · Aging Cell

Retinal Development and DisordersRetinal Diseases and Treatments

Cited by 109

Neuroprotection by the stable nitroxide tempol during reperfusion in a rat model of transient focal ischemia

Rak, R., Chao, D. L., Pluta, R. M., Mitchell, J. B., Oldfield, E. H., & Watson, J. C. (2000) · Journal of Neurosurgery

Neuroprotection in Cerebral IschemiaAcute Ischemic Stroke Management

Cited by 106

A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration

Jackson, T. L., Slakter, J., Buyse, M., Wang, K., Dugel, P. U., Wykoff, C. C., Boyer, D. S., Gerometta, M., Baldwin, M. E., Price, C. F., et al. (2023) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 55